Can a Synbiotic Supplementation Contribute to Decreasing Anti-Tissue Transglutaminase Levels in Children with Potential Celiac Disease?
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Synbiotics can alleviate some intestinal pathologies or prevent trigger mechanisms for some diseases such as celiac disease (CD). If patients with high levels of anti-tissue transglutaminase (anti-tTG) immunoglobulin A (IgA) antibodies have normal duodenal histology, they are followed as potential CD patients. The aim of this study was to investigate the effect of synbiotic use on the blood levels of anti-tTG antibodies in children. Methods: Eighty-two patients with high anti-tTG levels were included in this study. Patients were randomly divided into two groups. The synbiotic group was treated with a daily dose of a synbiotic including multi-strain probiotics for 20 days. The control group was not administered any medication. Anti-tTG values at baseline and repeat measurements and the percentage change in anti-tTG levels between groups were compared. Results: The anti-tTG level at baseline was 36 U/mL (interquartile range [IQR], 26.4–68 U/mL) in the synbiotic group, and it decreased significantly to 13 U/mL (IQR, 6.5–27.5 U/mL) after 20 days (p<0.05). The anti-tTG level at baseline was 46 U/mL (IQR, 31–89 U/mL) in the control group, which also decreased significantly to 23 U/mL (IQR, 7–41 U/mL) after 20 days (p<0.05). Anti-tTG levels exhibited 73% and 56% decreases in the synbiotic and control groups, respectively (p<0.05). Conclusion: It may be speculated that a synbiotic supplementation can contribute to decreasing anti-tTG levels in children with potential CD.
Abstract
Purpose: Synbiotics can alleviate some intestinal pathologies or prevent trigger mechanisms for some diseases such as celiac disease (CD). If patients with high levels of anti-tissue transglutaminase (anti-tTG) immunoglobulin A (IgA) antibodies have normal duodenal histology, they are followed as potential CD patients. The aim of this study was to investigate the effect of synbiotic use on the blood levels of anti-tTG antibodies in children. Methods: Eighty-two patients with high anti-tTG levels were included in this study. Patients were randomly divided into two groups. The synbiotic group was treated with a daily dose of a synbiotic including multi-strain probiotics for 20 days. The control group was not administered any medication. Anti-tTG values at baseline and repeat measurements and the percentage change in anti-tTG levels between groups were compared. Results: The anti-tTG level at baseline was 36 U/mL (interquartile range [IQR], 26.4–68 U/mL) in the synbiotic group, and it decreased significantly to 13 U/mL (IQR, 6.5–27.5 U/mL) after 20 days (p<0.05). The anti-tTG level at baseline was 46 U/mL (IQR, 31–89 U/mL) in the control group, which also decreased significantly to 23 U/mL (IQR, 7–41 U/mL) after 20 days (p<0.05). Anti-tTG levels exhibited 73% and 56% decreases in the synbiotic and control groups, respectively (p<0.05). Conclusion: It may be speculated that a synbiotic supplementation can contribute to decreasing anti-tTG levels in children with potential CD.
참고문헌 (25)
- Iannitti T, "Therapeutical use of probiotic formulations in clinical practice", Clin Nutr, 29, pp.701~725 (2010)
- Gagliardi A, "Rebuilding the gut microbiota ecosystem", Int J Environ Res Public Health, 15, pp.1679~ (2018)
- Husby S, "European Society for Pediatric Gastroenterology, Hepatology, and Nutrition guidelines for the diagnosis of coeliac disease", J Pediatr Gastroenterol Nutr, 54, pp.136~160 (2012)
- Guandalini S, "Celiac disease : a review", JAMA Pediatr, 168, pp.272~278 (2014)
- Silvester JA, "Tests for serum transglutaminase and endomysial antibodies do not detect most patients with celiac disease and persistent villous atrophy on gluten-free diets : a meta-analysis", Gastroenterology, 153, pp.689~701 (2017)
- Di Sabatino A, "The function of tissue transglutaminase in celiac disease", Autoimmun Rev, 11, pp.746~753 (2012)
- Lindfors K, "Transglutaminase 2-targeted autoantibodies in celiac disease: pathogenetic players in addition to diagnostic tools?", Autoimmun Rev, 9, pp.744~749 (2010)
- Kumar J, "Physiopathology and management of gluten-induced celiac disease", J Food Sci, 82, pp.270~277 (2017)
- Vriezinga SL, "Randomized feeding intervention in infants at high risk for celiac disease", N Engl J Med, 371, pp.1304~1315 (2014)
- Borrelli M, "Intestinal anti-transglutaminase 2 immunoglobulin A deposits in children at risk for coeliac disease(CD) : data from the PreventCD study", Clin Exp Immunol, 191, pp.311~317 (2018)
- Veeraraghavan G, "Celiac disease 2015 update : new therapies", Expert Rev Gastroenterol Hepatol, 9, pp.913~927 (2015)
- Kho ZY, "The human gut microbiome-a potential controller of wellness and disease", Front Microbiol, 9, pp.1835~ (2018)
- Losurdo G, "The interaction between celiac disease and intestinal microbiota", J Clin Gastroenterol, 50(Suppl 2), pp.145~147 (2016)
- Marasco G, "Gut microbiota and celiac disease", Dig Dis Sci, 61, pp.1461~1472 (2016)
- Girbovan A, "Dysbiosis a risk factor for celiac disease", Med Microbiol Immunol, 206, pp.83~91 (2017)
- Cenit MC, "Intestinal microbiota and celiac disease : cause, consequence or co-evolution", Nutrients, 7, pp.6900~6923 (2015)
- Galipeau HJ, "Intestinal microbiota modulates gluten-induced immunopathology in humanized mice", Am J Pathol, 185, pp.2969~2982 (2015)
- Lindfors K, "Live probiotic Bifidobacterium lactis bacteria inhibit the toxic effects induced by wheat gliadin in epithelial cell culture", Clin Exp Immunol, 152, pp.552~558 (2008)
- Smecuol E, "Exploratory, randomized, double-blind, placebo-controlled study on the effects of Bifidobacterium infantis natren life start strain super strain in active celiac disease", J Clin Gastroenterol, 47, pp.139~147 (2013)
- Orlando A, "Lactobacillus GG restoration of the gliadin induced epithelial barrier disruption : the role of cellular polyamines", BMC Microbiol, 14, pp.19~ (2014)
- De Angelis M, "VSL#3 probiotic preparation has the capacity to hydrolyze gliadin polypeptides responsible for Celiac Sprue", Biochim Biophys Acta, 1762, pp.80~93 (2006)
- Harnett J, "Probiotics and the microbiome in celiac disease : a randomised controlled trial", Evid Based Complement Alternat Med, 2016, pp.9048574~ (2016)
- Francavilla R, "Clinical and microbiological effect of a multispecies probiotic supplementation in celiac patients with persistent IBS-type symptoms : a randomized, double-blind, placebo-controlled, multicenter trial", J Clin Gastroenterol, 53, pp.e117~25 (2019)
- De Palma G, "Pivotal advance : bifidobacteria and Gram-negative bacteria differentially influence immune responses in the proinflammatory milieu of celiac disease", J Leukoc Biol, 87, pp.765~778 (2010)
- Husby S, "European Society Paediatric Gastroenterology, Hepatology and Nutrition guidelines for diagnosing coeliac disease 2020", J Pediatr Gastroenterol Nutr, 70, pp.141~156 (2020)